<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="migraine/PMC6380461/results/search/country/results.xml">
  <result pre="http://orcid.org/0000-0003-0400-1951 Reichert Janice M. b [a], Institut de Recherches Servier" exact="France" post="[b], The Antibody Society USA CONTACT Janice M. Reichert"/>
  <result pre="a first approval in either the European Union (EU) or" exact="United States" post="(US). As of November 2018, 4 antibody therapeutics (sacituzumab"/>
  <result pre="therapeutics granted first approvals in the European Union or the" exact="United States" post="during 2018*. International non-proprietary name# Brand name Target; Format"/>
  <result pre="G; NA, not applicable; PD-1 programmed cell death 1; US," exact="United States." post="Erenumab (Novartis) On May 17, 2018, the US Food"/>
  <result pre="or vorinostat. Study sites were located in the US, Europe," exact="Japan" post="and Australia. Median progression-free survival (PFS) was 7.6 months"/>
  <result pre="interleukin; NA, not applicable; TROP-2, trophoblast cell-surface antigen 2; US," exact="United States." post="Sacituzumab govitecan (Immunomedics) This antibody-drug conjugate (ADC) is composed"/>
  <result pre="review in the EU. Antibody therapeutics undergoing regulatory review in" exact="China" post="A decade ago, when the ‘Antibodies to watch’ article"/>
  <result pre="for relapsed and refractory classical Hodgkin’s lymphoma was submitted in" exact="China" post="and granted priority review status. In the Phase 2"/>
  <result pre="Ltd Camrelizumab Humanized IgG4 PD-1 Phase 3; regulatory review in" exact="China" post="Hodgkin’s lymphoma, hepatocellular carcinoma Actinium Pharmaceuticals I-131-BC8, Iomab-B Murine"/>
  <result pre="Tislelizumab (BGB-A317) Humanized mAb PD-1 Phase 3; regulatory review in" exact="China" post="Non-small cell lung cancer, Hodgkin’s lymphoma Innovent Biologics (Suzhou)"/>
  <result pre="Ltd. IBI308 Human mAb PD-1 Phase 3; regulatory review in" exact="China" post="Squamous cell non-small cell lung cancer CStone Pharmaceuticals CS1001"/>
  <result pre="fragment SCLC small cell lung cancer SS Sézary syndrome US" exact="United States" post="XLH X-linked hypophosphatemia Disclosure Potential Conflicts of Interest No"/>
  <result pre="drug application for anti-PD-1 antibody tislelizumab in Hodgkin’s lymphoma in" exact="China" post=". 8 31, 2018 press release http://ir.beigene.com/phoenix.zhtml?c=254246&amp;amp;p=irol-newsArticle&amp;amp;ID=2365642. 52. collab:"/>
  <result pre="Congress of the European Hematology Association, 2018 6 16; Stockholm," exact="Sweden" post="https://www.primeoncology.org/app/uploads/hematology-updates-stockholm-2018-dlbcl-s802-sehn.pdf 77. collab: Roche Roche virtual late stage pipeline"/>
 </snippets>
</snippetsTree>
